VTGN
VTGN
NASDAQ · Biotechnology

Vistagen Therapeutics Inc

$0.60
+0.03 (+5.16%)
Financial Highlights (FY 2026)
Revenue
648.8K
Net Income
-68,814,722
Gross Margin
Profit Margin
-10,579.8%
Rev Growth
-24.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 37.6% 37.6%
Operating Margin -11,517.1% -10,365.4% 26.4% 28.6%
Profit Margin -10,579.8% -10,050.9% 22.0% 24.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 648.8K 854.4K 9.03M 9.73M
Gross Profit 3.40M 3.66M
Operating Income -74,718,899 -88,564,479 2.39M 2.78M
Net Income -68,814,722 -81,566,244 1.99M 2.35M
Gross Margin 37.6% 37.6%
Operating Margin -11,517.1% -10,365.4% 26.4% 28.6%
Profit Margin -10,579.8% -10,050.9% 22.0% 24.2%
Rev Growth -24.1% -24.1% +1.4% +15.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 10.09M 8.64M
Total Equity 16.52M 14.60M
D/E Ratio 0.61 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -74,703,210 -93,465,098 3.04M 3.38M
Free Cash Flow 1.40M 2.01M